Lynparza shows promise in preventing cancer recurrence
Lynparza is the first medicine targeting BRCA mutations to show clinical benefit in adjuvant setting
Read More
Tag: ASCO
UK study highlights potential of genetic screening for prostate cancer
Genetic ‘barcoding’ in GP surgeries can identify men at higher risk of prostate cancer, researchers claim
Read More
Tagrisso shows ‘unprecedented’ disease free survival in lung cancer
The Phase III ADAURA trial showed treatment with Tagrisso after surgery with curative intent the the risk of disease recurrence or death by around 80%
Read More
MSD’s Keytruda doubles PFS in bowel cancer subset
The ‘game-changing’ results will likely result in a paradigm shift in current clinical practice, researchers said
Read More
Lynparza ASCO success continues with positive ovarian cancer results
The treatment achieved a 72% objective response rate in patients with previously treated germline BRCA1/2-mutated advanced ovarian cancer.
Read More
Janssen presents positive Darzalex results at ASCO
The drug showed non-inferior efficacy and a significantly higher complete response rate in two different trials.
Read More
‘Unprecedented’ results in AZ’ late-stage Lynparza trial
The results were announced at the 2019 ASCO meeting.
Read More
Data backs first-line use of Roche’s Tecentriq
Roche’ bladder cancer drug Tecentriq shrank tumours in 24 percent of patients previously untreated for the disease, raising hopes that it might be approved in the first-line setting.
Read More
J&J’s Darzalex improves outcomes in multiple myeloma trial
Adding Johnson & Johnson’s Darzalex to the standard regimen of Takeda’s Velcade and dexamethasone significantly improved outcomes for patients with recurrent or refractory multiple myeloma, show findings of a late-stage trial.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
